Letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by P. Barrière, S. Hamamah, E. Arbo, C. Avril, B. Salle, J.-L. Pouly, et al. (J Gynecol Obstet Hum Reprod. 2023;52(1):102510)

Affiliations

• ¹ Merck KGaA, Darmstadt, Germany. Electronic address: susana.montenegro@merckgroup.com.
• ² Merck KGaA, Darmstadt, Germany.
• ³ Merck Santé, France, an affiliate of Merck KGaA, Darmstadt, Germany.
• ⁴ Horiana company, Bordeaux, France.
• ⁵ Merck KGaA, Darmstadt, Germany; Unit of Endocrinology, PhD School of Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Reggio Emilia 42121, Italy.
• ⁶ Merck KGaA, Darmstadt, Germany; Department of Development and Regeneration, Laboratory of Endometrium, Endometriosis & Reproductive Medicine, KU Leuven, Leuven, Belgium; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University Medical School, New Haven, United States.